Optimized/VBN
Internal/JJ
Control/NN
and/CC
Gene/NN
Expression/NN
Analysis/NN
in/IN
Epstein-Barr/JJ
Virus-Transformed/JJ
Lymphoblastoid/JJ
Cell/NN
Lines/NNS
./.
====================
The/DT
Epstein-Barr/JJ
virus-transformed/JJ
lymphoblastoid/JJ
cell/NN
line/NN
(/(
LCL/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
major/JJ
genomic/JJ
resources/NNS
for/IN
human/JJ
genetics/NNS
and/CC
immunological/JJ
studies/NNS
./.
====================
Use/NN
of/IN
LCLs/NNS
is/VBZ
currently/RB
extended/VBD
to/TO
pharmacogenetic/JJ
studies/NNS
to/TO
investigate/VB
variations/NNS
in/IN
human/JJ
gene/NN
expression/NN
as/IN
well/RB
as/IN
drug/NN
responses/NNS
between/IN
individuals/NNS
./.
====================
We/PRP
evaluated/VBD
four/CD
common/JJ
internal/JJ
controls/NNS
for/IN
gene/NN
expression/NN
analysis/NN
of/IN
selected/VBN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
expression/NN
pattern/NN
analyses/NNS
showed/VBD
that/IN
TBP/NN
(/(
TATA/NN
box-binding/VBG
protein/NN
)/)
is/VBZ
a/DT
suitable/JJ
internal/JJ
control/JJ
for/IN
normalization/NN
,/,
whereas/IN
GAPDH/NN
(/(
glyceraldehyde3phosphate/NN
dehydrogenase/NN
)/)
is/VBZ
not/RB
a/DT
good/JJ
internal/JJ
control/JJ
for/IN
gene/NN
expression/NN
analyses/NNS
of/IN
hematopoiesisrelated/JJ
genes/NNS
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
at/IN
different/JJ
subculture/NN
passages/NNS
./.
====================
Using/VBG
the/DT
TBP/NN
normalizer/CC
,/,
we/PRP
found/VBD
significant/JJ
gene/NN
expression/NN
changes/NNS
in/IN
selected/VBN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
(/(
downregulation/NN
of/IN
RUNX1/NN
,/,
RUNX3/NN
,/,
CBFB/NN
,/,
TLE1/NN
,/,
and/CC
NOTCH2/NN
;/:
upregulation/NN
of/IN
MSC/NN
and/CC
PLAGL2/NN
)/)
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
at/IN
different/JJ
passage/NN
numbers/NNS
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
these/DT
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
are/VBP
potential/JJ
cellular/JJ
targets/NNS
of/IN
EBV/NN
infection/NN
,/,
contributing/VBG
to/TO
EBV-mediated/JJ
B-cell/NN
transformation/NN
and/CC
LCL/NN
immortalization/NN
./.
====================
Keywords/NNS
:/:
lymphoblastoid/JJ
cell/NN
line/NN
,/,
internal/JJ
control/JJ
,/,
quantitative/JJ
real-time/NN
polymerase/NN
chain/NN
reactionEBVinfected/VBN
B/NN
cells/NNS
are/VBP
transformed/VBN
into/IN
continuously/RB
proliferating/VBG
lymphoblastoid/JJ
cell/NN
lines/NNS
(/(
LCLs/NNS
)/)
,/,
which/WDT
provide/VBP
genomic/JJ
resources/VBZ
for/IN
human/JJ
genetics/NNS
and/CC
immunological/JJ
studies/NNS
./.
====================
However/RB
,/,
there/EX
is/VBZ
a/DT
limitation/NN
of/IN
LCL/NN
utilization/NN
,/,
due/JJ
to/TO
possible/JJ
genetic/JJ
changes/NNS
in/IN
the/DT
process/NN
of/IN
EBV/NN
transformation/NN
(/(
Shukla/NN
and/CC
Dolan/NN
,/,
2005/CD
;/:
Haas/NNS
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
It/PRP
is/VBZ
controversial/JJ
that/DT
LCLs/NNS
are/VBP
suitable/JJ
as/IN
an/DT
experimental/JJ
material/NN
of/IN
genomewide/NN
association/NN
studies/NNS
(/(
SimonSanchez/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
Nonetheless/RB
,/,
the/DT
use/NN
of/IN
LCLs/NNS
is/VBZ
currently/RB
extended/VBD
to/TO
pharmacogenetic/JJ
studies/NNS
to/TO
investigate/VB
variations/NNS
in/IN
human/JJ
gene/NN
expression/NN
as/IN
well/RB
as/IN
drug/NN
responses/NNS
between/IN
individuals/NNS
./.
====================
For/IN
example/NN
,/,
gene/NN
expression/NN
phenotypes/NNS
were/VBD
investigated/VBN
in/IN
LCLs/NNS
for/IN
the/DT
relative/JJ
impact/NN
of/IN
nucleotide/NN
and/CC
copy/NN
number/NN
variation/NN
(/(
Stranger/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
EBV/NN
infection/NN
induces/VBZ
gene/NN
expression/NN
changes/NNS
in/IN
B/NN
cells/NNS
,/,
contributing/VBG
to/TO
immortalization/NN
./.
====================
A/DT
number/NN
of/IN
cellular/JJ
genes/NNS
have/VBP
been/VBN
identified/VBN
as/IN
targets/NNS
of/IN
EBV/NN
infection/NN
in/IN
various/JJ
systems/NNS
,/,
including/VBG
inducible/JJ
and/CC
stable/JJ
lymphoma/NN
cell/NN
lines/NNS
that/WDT
have/VBP
been/VBN
transfected/VBN
with/IN
particular/JJ
viral/JJ
gene/NN
expression/NN
vectors/NNS
or/CC
infected/JJ
with/IN
EBV/NN
(/(
Carter/NN
et/FW
al./FW
,/,
2002/CD
;/:
Kelly/RB
et/FW
al./FW
,/,
2002/CD
;/:
Cahir/NNP
McFarland/CC
et/FW
al./FW
,/,
2004/CD
;/:
Kang/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
For/IN
gene/NN
expression/NN
analysis/NN
,/,
appropriate/JJ
internal/JJ
controls/NNS
should/MD
be/VB
carefully/RB
selected/VBN
to/TO
normalize/VB
the/DT
expression/NN
of/IN
target/NN
genes/NNS
in/IN
LCLs/NNS
./.
====================
Generally/RB
,/,
housekeeping/JJ
genes/NNS
are/VBP
used/VBN
as/IN
internal/JJ
controls/NNS
for/IN
gene/NN
expression/NN
studies/NNS
,/,
assuming/VBG
that/DT
such/JJ
genes/NNS
exhibit/VBP
relatively/RB
constant/JJ
basal/JJ
levels/NNS
of/IN
gene/NN
expression/NN
under/IN
all/DT
conditions/NNS
./.
====================
However/RB
,/,
not/RB
all/DT
housekeeping/JJ
genes/NNS
are/VBP
always/RB
applied/VBN
to/TO
the/DT
normalization/NN
of/IN
gene/NN
expression/NN
data/NNS
under/IN
all/DT
conditions/NNS
(/(
Thellin/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
the/DT
comparison/NN
of/IN
target/NN
gene/NN
expression/NN
needs/VBZ
particular/JJ
internal/JJ
controls/NNS
that/IN
are/VBP
suitable/JJ
in/IN
different/JJ
tissues/NNS
or/CC
different/JJ
physiological/JJ
conditions/NNS
in/IN
human/JJ
and/CC
other/JJ
organisms/NNS
(/(
Selvey/NNP
et/FW
al./FW
,/,
2001/CD
;/:
Vandesompele/NN
et/FW
al./FW
,/,
2002/CD
;/:
Lossos/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Filby/RB
and/CC
Tyler/NN
,/,
2007/CD
;/:
Theis/DT
et/FW
al./FW
,/,
2007/CD
;/:
Rho/NN
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
Among/IN
housekeeping/JJ
genes/NNS
,/,
GAPDH/JJ
has/VBZ
been/VBN
demonstrated/VBN
to/TO
be/VB
a/DT
good/JJ
internal/JJ
control/JJ
in/IN
tumor/NN
cell/NN
lines/NNS
(/(
Janssens/NNS
et/FW
al./FW
,/,
2004/CD
)/)
,/,
while/IN
HPRT/NN
has/VBZ
been/VBN
identified/VBN
as/IN
a/DT
good/JJ
reference/VBP
gene/NN
for/IN
cancer/NN
research/NN
when/WRB
comparing/VBG
solid/JJ
tumor/NN
tissue/NN
samples/NNS
with/IN
normal/JJ
tissue/NN
samples/NNS
(/(
de/FW
Kok/NN
et/FW
al./FW
,/,
2005/CD
;/:
Ohl/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
recommended/VBN
that/DT
suitable/JJ
internal/JJ
controls/NNS
should/MD
be/VB
determined/VBN
for/IN
accu/VBG
rate/NN
normalization/NN
of/IN
gene/NN
expression/NN
data/NNS
./.
====================
For/IN
peripheral/JJ
blood/NN
cells/NNS
or/CC
leukemia/lymphoma/NN
cell/NN
lines/NNS
,/,
GAPDH/NN
is/VBZ
frequently/RB
used/VBN
to/TO
normalize/VB
gene/NN
expression/NN
data/NNS
(/(
Natkunam/NN
et/FW
al./FW
,/,
2005/CD
;/:
Saunders/NNS
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
According/VBG
to/TO
our/PRP$
previous/JJ
microarray/NN
data/NNS
,/,
the/DT
choice/NN
of/IN
GAPDH/NN
may/MD
be/VB
problematic/JJ
as/IN
an/DT
internal/JJ
control/JJ
of/IN
gene/NN
expression/NN
analysis/NN
before/IN
and/CC
after/IN
EBV/NN
infection/NN
./.
====================
In/IN
addition/NN
,/,
as/IN
the/DT
use/NN
of/IN
LCLs/NNS
is/VBZ
expanded/VBN
to/TO
various/JJ
areas/NNS
of/IN
genomics/NNS
,/,
including/VBG
pharamcogenomics/NNS
,/,
gene/NN
expression/NN
analysis/NN
of/IN
LCLs/NNS
needs/VBZ
optimized/VBN
internal/JJ
controls/NNS
./.
====================
Here/RB
,/,
we/PRP
evaluated/VBD
four/CD
common/JJ
internal/JJ
controls/NNS
for/IN
gene/NN
expression/NN
analysis/NN
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
,/,
applying/VBG
them/PRP
to/TO
an/DT
expression/NN
analysis/NN
of/IN
selected/VBN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
./.
====================
TBP/NN
was/VBD
finally/RB
selected/VBN
as/IN
an/DT
optimal/JJ
internal/JJ
control/JJ
for/IN
gene/NN
expression/NN
analysis/NN
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
./.
====================
Peripheral/JJ
blood/NN
was/VBD
obtained/VBN
from/IN
the/DT
Jungang/NN
Blood/NN
Center/NN
of/IN
the/DT
Korean/JJ
Red/JJ
Cross/NN
./.
====================
FicollHypaque/NN
gradient/NN
centrifugation/NN
was/VBD
performed/VBN
to/TO
isolate/VB
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
(/(
Amersham/NN
)/)
./.
====================
Primary/JJ
CD19/NN
(/(
+/JJ
)/)
B/NN
cells/NNS
were/VBD
then/RB
purified/VBN
by/IN
negative/JJ
selection/NN
using/VBG
a/DT
B/NN
cell/NN
isolation/NN
kit/NN
(/(
Miltenyi/NNP
Biotech/NNP
)/)
./.
====================
EBV/NN
viral/JJ
stock/NN
was/VBD
collected/VBN
from/IN
the/DT
culture/NN
of/IN
an/DT
EBV-transformed/JJ
B958/NN
marmoset/NN
cell/NN
line/NN
,/,
which/WDT
was/VBD
maintained/VBN
at/IN
37oC/NN
and/CC
5/CD
%/NN
CO2/NN
for/IN
4∼7/CD
days/NNS
and/CC
then/RB
stored/VBD
at/IN
－80oC/NN
until/IN
needed/VBD
./.
====================
EBV/NN
infection/NN
of/IN
primary/JJ
B/NN
cells/NNS
and/CC
LCL/NN
generation/NN
were/VBD
performed/VBN
as/IN
described/VBN
elsewhere/RB
(/(
Hur/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Briefly/RB
,/,
EBV-infected/JJ
B-cells/NNS
were/VBD
incubated/VBN
in/IN
RPMI-1640/NN
supplemented/VBN
with/IN
10/CD
%/NN
FBS/NN
and/CC
penicillin-streptomycin/NN
(/(
100μg/100/CD
unit/NN
)/)
for/IN
10∼20/CD
days/NNS
until/IN
clumps/NNS
of/IN
EBV-infected/JJ
B/NN
cells/NNS
were/VBD
visible/JJ
./.
====================
The/DT
culture/NN
medium/NN
was/VBD
then/RB
changed/VBD
with/IN
fresh/JJ
complete/JJ
medium/NN
for/IN
subsequent/JJ
subculture/NN
./.
====================
When/WRB
cell/NN
numbers/NNS
of/IN
EBV-infected/JJ
B-cells/NNS
reached/VBD
approximately/RB
10/CD
million/NN
cells/NNS
per/IN
culture/NN
flask/JJ
,/,
the/DT
cells/NNS
were/VBD
used/VBN
for/IN
the/DT
next/JJ
passage/NN
at/IN
a/DT
seeding/JJ
density/NN
of/IN
2∼5×105/CD
cells//JJ
ml/NN
./.
====================
At/IN
this/DT
point/NN
,/,
the/DT
LCL/NN
was/VBD
referred/VBN
as/IN
passage/NN
number/NN
1/CD
./.
====================
Next/RB
,/,
the/DT
LCL/NN
culture/NN
was/VBD
divided/VBN
for/IN
continuous/JJ
subculture/NN
with/IN
fresh/JJ
medium/NN
approximately/RB
twice/RB
per/IN
week/NN
and/CC
maintained/VBD
to/TO
passage/NN
number/NN
100/CD
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
B-cells/NNS
and/CC
counterpart/NN
LCLs/NNS
from/IN
three/CD
donors/NNS
using/VBG
Trizol/NN
(/(
Invitrogen/NN
)/)
and/CC
treated/VBN
with/IN
DNase/NN
I/CD
prior/JJ
to/TO
the/DT
synthesis/NN
of/IN
firststrand/JJ
cDNA/NN
using/VBG
oligo/JJ
(/(
dT/JJ
)/)
primer/NN
and/CC
the/DT
Superscript/NN
II/CD
reverse/JJ
transcription/NN
kit/NN
(/(
Invitrogen/NN
)/)
./.
====================
Semiquantitative/JJ
RT/NN
PCR/NN
was/VBD
performed/VBN
for/IN
some/DT
selected/VBN
genes/NNS
./.
====================
Gene/NN
expression/NN
levels/NNS
of/IN
some/DT
selected/VBN
genes/NNS
were/VBD
estimated/VBN
by/IN
semiquantitative/JJ
RTPCR/NN
with/IN
the/DT
following/VBG
conditions/NNS
:/:
25/CD
cycles/NNS
of/IN
40/CD
sec/JJ
at/IN
94oC/JJ
,/,
40/CD
sec/JJ
at/IN
60oC/JJ
,/,
and/CC
100/CD
sec/JJ
at/IN
72oC/JJ
for/IN
RUNX3/NN
,/,
MSC/NN
,/,
and/CC
GAPDH/NN
and/CC
32/CD
cycles/NNS
for/IN
NOTCH2/NN
and/CC
TLE1/NN
./.
====================
For/IN
quantitative/JJ
realtime/RB
PCR/NN
,/,
amplification/RB
mixtures/VBZ
(/(
50/CD
ul/JJ
)/)
contained/VBD
10∼100/CD
ng/NN
of/IN
firststrand/DT
cDNA/NN
template/RB
,/,
25/CD
ul/JJ
of/IN
2×/DT
SYBR/NN
Green/NNP
Master/NNP
Mix/NNP
buffer/CC
(/(
Invitrogen/NNP
)/)
,/,
and/CC
600/CD
nM/NN
of/IN
forward/JJ
and/CC
reverse/JJ
primers/NNS
(/(
Table/JJ
1/LS
)/)
for/IN
:/:
control/JJ
genes/NNS
βactin/RB
(/(
ACTB/NNP
)/)
,/,
glyceraldehyde3phosphate/RB
dehydrogenase/RB
(/(
GAPDH/NNP
)/)
,/,
β2microglobulin/RB
(/(
B2M/NNP
)/)
,/,
and/CC
TATA/NN
boxbinding/VBG
protein/NN
(/(
TBP/NN
)/)
;/:
and/CC
target/RB
genes/NNS
pleiomorphic/JJ
adenoma/NN
genelike/IN
2/CD
(/(
PLAGL2/NN
)/)
,/,
musculin/RB
(/(
MSC/NNP
)/)
/activated/JJ
Bcell/NNP
factor/IN
(/(
ABF1/NNP
)/)
,/,
transducinlike/IN
enhancer/NN
of/IN
split/JJ
1/LS
(/(
TLE1/NNP
)/)
,/,
Notch/NNP
homolog/NN
2/CD
(/(
NOTCH2/NNP
)/)
,/,
Runtrelated/JJ
transcription/NN
factor/NN
1/LS
(/(
RUNX1/NNP
)/)
,/,
Runtrelated/JJ
transcription/NN
factor/NN
3/LS
(/(
RUNX3/NNP
)/)
,/,
and/CC
core/RB
binding/VBG
factor/NN
beta/NN
subunit/RB
(/(
CBFB/NN
)/)
./.
====================
PCR/NN
cycles/NNS
were/VBD
95oC/JJ
for/IN
10/CD
min/NN
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
95oC/JJ
for/IN
15/CD
sec/JJ
,/,
and/CC
60oC/JJ
for/IN
1/CD
min/NN
./.
====================
Reactions/NNS
were/VBD
run/JJ
on/IN
an/DT
ABI/NN
HT/NN
7900/CD
(/(
Applied/VBN
Biosystems/NNS
)/)
./.
====================
Relative/JJ
expression/NN
levels/NNS
,/,
Δ/NNP
(/(
CTgeneCTcontrol/NN
)/)
,/,
were/VBD
displayed/VBN
as/IN
the/DT
difference/NN
in/IN
CT/NN
(/(
threshold/NN
cycle/NN
)/)
between/IN
genes/NNS
of/IN
interest/NN
and/CC
internal/JJ
control/JJ
genes/NNS
./.
====================
For/IN
the/DT
correlation/NN
coefficient/JJ
analysis/NN
of/IN
gene/NN
expression/NN
patterns/NNS
,/,
expression/NN
levels/NNS
of/IN
particular/JJ
genes/NNS
of/IN
interest/NN
were/VBD
normalized/VBN
to/TO
four/CD
different/JJ
reference/NN
genes/NNS
./.
====================
Then/RB
,/,
correlation/NN
coefficients/NNS
were/VBD
calculated/VBN
from/IN
the/DT
expression/NN
levels/NNS
(/(
CT/NN
values/NNS
)/)
,/,
normalized/VBN
to/TO
pairs/NNS
of/IN
reference/NN
genes/NNS
(/(
e./FW
g./FW
,/,
ACTB/NN
vs/CC
TBP/NN
,/,
ACTB/NN
vs/CC
B2M/NN
,/,
ACTB/NN
vs/CC
GAPDH/NN
,/,
TBP/NN
vs/CC
B2M/NN
,/,
TBP/NN
vs/CC
GAPDH/NN
,/,
B2M/NN
vs/CC
GAPDH/NN
)/)
./.
====================
To/TO
address/VB
the/DT
question/NN
of/IN
whether/IN
GAPDH/JJ
is/VBZ
a/DT
suit/JJ
able/JJ
internal/JJ
control/JJ
for/IN
gene/NN
expression/NN
analysis/NN
of/IN
various/JJ
types/NNS
of/IN
LCLs/NNS
,/,
we/PRP
evaluated/VBD
four/CD
common/JJ
housekeeping/JJ
genes/NNS
as/IN
internal/JJ
control/JJ
genes/NNS
./.
====================
First/RB
,/,
we/PRP
extracted/VBD
expression/NN
data/NNS
on/IN
ACTB/NN
,/,
TBP/NN
,/,
B2M/NN
,/,
and/CC
GAPDH/NN
as/IN
well/RB
as/IN
some/DT
genes/NNS
of/IN
interest/JJ
from/IN
our/PRP$
previous/JJ
microarray/NNS
data/NNS
(/(
Baik/NN
et/FW
al./FW
,/,
2007/CD
)/)
,/,
indicating/VBG
upregulation/NN
of/IN
GAPDH/JJ
and/CC
ACTB/NN
in/IN
LCLs/NNS
compared/VBN
to/TO
B/NN
cells/NNS
./.
====================
However/RB
,/,
TBP/NN
and/CC
B2M/NN
exhibited/VBD
less/RBR
than/IN
a/DT
2-fold/JJ
change/NN
between/IN
B-cells/NNS
and/CC
LCLs/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
In/IN
addition/NN
,/,
with/IN
regard/NN
to/TO
B/NN
cell/NN
transformation/NN
,/,
some/DT
genes/NNS
of/IN
interest/NN
were/VBD
randomly/RB
selected/VBN
for/IN
expression/NN
studies/NNS
of/IN
hematopoiesis/NN
and/CC
lymphomagenesisrelated/JJ
genes/NNS
./.
====================
Our/PRP$
microarray/NN
data/NNS
showed/VBD
that/IN
PLAGL2/NN
,/,
MSC/NN
,/,
TLE1/NN
,/,
RUNX1/NN
,/,
and/CC
NOTCH2/NN
exhibited/VBD
significant/JJ
changes/NNS
in/IN
gene/NN
expression/NN
levels/NNS
between/IN
Bcells/NNS
and/CC
LCLs/NNS
(/(
Table/JJ
2/CD
)/)
,/,
whereas/IN
the/DT
other/JJ
genes/NNS
(/(
i./FW
e./FW
,/,
RUNX3/NN
,/,
CBFB/NN
)/)
exhibited/VBD
less/RBR
than/IN
a/DT
2-fold/JJ
change/NN
./.
====================
For/IN
these/DT
selected/VBN
genes/NNS
,/,
RT-PCR/NN
had/VBD
similar/JJ
gene/NN
expression/NN
patterns/NNS
for/IN
RUNX3/NN
,/,
MSC/NN
,/,
TLE1/NN
,/,
and/CC
NOTCH2/NN
as/IN
the/DT
microarray/NN
data/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Four/CD
common/JJ
housekeeping/JJ
genes/NNS
were/VBD
included/VBN
in/IN
the/DT
quantitative/JJ
real-time/NN
PCR/NN
of/IN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
so/RB
that/IN
relative/JJ
gene/NN
expression/NN
levels/NNS
could/MD
be/VB
obtained/VBN
by/IN
normalization/NN
./.
====================
In/IN
a/DT
comparison/NN
of/IN
gene/NN
expression/NN
only/RB
between/IN
B/NN
cells/NNS
and/CC
early/JJ
passages/NNS
of/IN
LCLs/NNS
,/,
similar/JJ
patterns/NNS
in/IN
hematopoietic/JJ
gene/NN
expression/NN
were/VBD
observed/VBN
when/WRB
normalized/VBN
by/IN
TBP/NN
,/,
ACTB/NN
,/,
and/CC
B2M/NN
but/CC
not/RB
by/IN
GAPDH/NN
(/(
Fig/NN
./.
====================
1B/NN
)/)
,/,
indicating/VBG
that/IN
the/DT
expression/NN
pattern/NN
of/IN
GAPDH/NN
deviated/VBN
from/IN
those/DT
of/IN
the/DT
other/JJ
housekeeping/JJ
genes/NNS
./.
====================
This/DT
result/NN
suggested/VBD
that/IN
GAPDH/NN
expression/NN
might/MD
be/VB
upregulated/VBN
in/IN
EBV-infected/JJ
B/NN
cells/NNS
during/IN
LCL/NN
generation/NN
./.
====================
Indeed/RB
,/,
GAPDH/NN
upregulation/NN
was/VBD
seen/VBN
in/IN
LCLs/NNS
of/IN
different/JJ
passage/NN
numbers/NNS
compared/VBN
with/IN
B/NN
cells/NNS
when/WRB
normalized/VBN
by/IN
TBP/NN
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
Next/RB
,/,
expression/NN
levels/NNS
of/IN
hematopoietic/JJ
genes/NNS
were/VBD
plotted/VBN
in/IN
reference/NN
to/TO
each/DT
internal/JJ
control/JJ
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
In/IN
a/DT
comparison/NN
of/IN
expression/NN
patterns/NNS
between/IN
B/NN
cells/NNS
and/CC
three/CD
different/JJ
time/NN
points/NNS
of/IN
long-term/JJ
subcultures/NNS
of/IN
LCLs/NNS
(/(
i./FW
e./FW
,/,
L1/NN
:/:
EBVinfected/JJ
B/NN
cells/NNS
,/,
L2/NN
:/:
early/JJ
passage/NN
LCLs/NNS
,/,
L3/NN
:/:
late/JJ
passage/NN
LCLs/NNS
)/)
,/,
correlation/NN
coefficients/NNS
of/IN
individual/JJ
expression/NN
patterns/NNS
were/VBD
calculated/VBN
by/IN
pair/NN
wise/RB
comparison/NN
of/IN
normalized/VBN
expression/NN
levels/NNS
using/VBG
four/CD
different/JJ
internal/JJ
controls/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
For/IN
seven/CD
genes/NNS
that/WDT
were/VBD
tested/VBN
,/,
TBPnormalized/JJ
expression/NN
levels/NNS
of/IN
each/DT
gene/NN
were/VBD
correlated/VBN
with/IN
ACTBnormalized/JJ
expression/NN
levels/NNS
,/,
whereas/IN
the/DT
worst/NN
correlation/NN
coefficients/NNS
of/IN
normalization/NN
between/IN
GAPDH/NN
and/CC
B2M/NN
were/VBD
seen/VBN
./.
====================
This/DT
result/NN
suggested/VBD
that/IN
TBP/NN
or/CC
ACTB/NN
might/MD
be/VB
a/DT
suitable/JJ
internal/JJ
control/JJ
for/IN
gene/NN
expression/NN
analyses/NNS
of/IN
hematopoiesisrelated/JJ
genes/NNS
in/IN
various/JJ
subculture/JJ
passages/NNS
of/IN
LCLs/NNS
./.
====================
However/RB
,/,
our/PRP$
previous/JJ
microarray/NN
data/NNS
showed/VBD
that/IN
ACTB/NN
was/VBD
upregulated/VBN
by/IN
about/RB
4/CD
fold/JJ
in/IN
LCLs/NNS
compared/VBN
with/IN
B/NN
cells/NNS
(/(
Baik/NN
et/FW
al/JJ
,/,
2007/CD
)/)
./.
====================
Therefore/RB
,/,
TBP/NN
was/VBD
finally/RB
selected/VBN
as/IN
an/DT
internal/JJ
control/JJ
for/IN
further/JJ
gene/NN
expression/NN
analysis/NN
of/IN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
of/IN
interest/NN
./.
====================
Next/RB
,/,
the/DT
optimized/VBN
internal/JJ
control/JJ
,/,
TBP/NN
,/,
was/VBD
applied/VBN
to/TO
the/DT
gene/NN
expression/NN
analysis/NN
of/IN
seven/CD
randomly/RB
selected/VBN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
in/IN
LCLs/NNS
./.
====================
Realtime/RB
PCR/NN
results/NNS
showed/VBD
that/IN
gene/NN
expression/NN
levels/NNS
of/IN
MSC/NN
,/,
TLE1/NN
,/,
RUNX1/NN
,/,
PLAGL2/NN
,/,
and/CC
GAPDH/NN
changed/VBD
dramatically/RB
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
,/,
whereas/IN
those/DT
of/IN
RUNX3/NN
and/CC
CBFB/NN
changed/VBD
slightly/RB
after/IN
EBV/NN
infection/NN
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
Interestingly/RB
,/,
the/DT
upregulation/NN
or/CC
downregulation/NN
patterns/NNS
that/WDT
were/VBD
detected/VBN
in/IN
EBVinfected/JJ
cells/NNS
were/VBD
sustained/JJ
until/IN
the/DT
middle/JJ
passage/NN
number/NN
(/(
100/CD
)/)
of/IN
LCLs/NNS
./.
====================
Thus/RB
,/,
these/DT
results/NNS
suggest/VBP
that/IN
dysregulation/NN
of/IN
these/DT
selected/VBN
hematopoietic/JJ
genes/NNS
may/MD
contribute/VB
to/TO
EBVmediated/JJ
B/NN
cell/NN
transformation/NN
and/CC
LCL/NN
immortalization/NN
./.
====================
Gene/NN
expression/NN
studies/NNS
of/IN
EBVtransformed/JJ
LCLs/NNS
have/VBP
commonly/RB
used/VBN
GAPDH/JJ
or/CC
ACTB/NN
as/IN
internal/JJ
controls/NNS
for/IN
normalization/NN
(/(
BaranMarszak/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
In/IN
our/PRP$
previous/JJ
study/NN
,/,
global/JJ
gene/NN
expression/NN
patterns/NNS
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
were/VBD
obtained/VBN
from/IN
our/PRP$
microarray/NN
analysis/NN
,/,
in/IN
which/WDT
GAPDH/NN
was/VBD
used/VBN
as/IN
an/DT
internal/JJ
control/JJ
for/IN
validation/NN
of/IN
gene/NN
expression/NN
(/(
Baik/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
In/IN
general/JJ
,/,
internal/JJ
control/JJ
genes/NNS
need/VBD
relatively/RB
constant/JJ
basal/JJ
levels/NNS
of/IN
gene/NN
expression/NN
in/IN
experimental/JJ
conditions/NNS
./.
====================
However/RB
,/,
our/PRP$
microarray/NN
data/NNS
suggested/VBD
that/IN
some/DT
housekeeping/JJ
genes/NNS
might/MD
be/VB
dysregulated/VBN
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
./.
====================
Therefore/RB
,/,
we/PRP
evaluated/VBD
four/CD
common/JJ
housekeeping/JJ
genes/NNS
as/IN
suitable/JJ
internal/JJ
controls/NNS
for/IN
the/DT
normalization/NN
of/IN
mRNA/NN
expression/NN
and/CC
applied/VBD
them/PRP
to/TO
a/DT
gene/NN
expression/NN
study/NN
of/IN
potential/JJ
cellular/JJ
target/NN
genes/NNS
of/IN
EBV/NN
infection/NN
./.
====================
Our/PRP$
results/NNS
showed/VBD
that/IN
the/DT
transcriptional/JJ
level/NN
of/IN
GAPDH/NN
increased/VBD
in/IN
the/DT
process/NN
of/IN
EBV-mediated/JJ
B-cell/NN
transformation/NN
./.
====================
The/DT
upregulation/NN
of/IN
GAPDH/NN
might/MD
be/VB
involved/VBN
in/IN
Bcell/NN
reprogramming/VBG
during/IN
LCL/NN
generation/NN
./.
====================
Alternatively/RB
,/,
GAPDH/NN
might/MD
be/VB
a/DT
direct/JJ
cellular/JJ
target/NN
gene/NN
of/IN
EBV/NN
infection/NN
./.
====================
Generally/RB
,/,
the/DT
expression/NN
of/IN
B/NN
cell-specific/JJ
genes/NNS
is/VBZ
lost/VBN
,/,
and/CC
B/NN
lineage-inappropriate/NN
genes/NNS
are/VBP
upregulated/VBN
during/IN
malignant/JJ
transformation/NN
of/IN
lymphoid/JJ
cells/NNS
,/,
suggesting/VBG
B-cell/NN
reprogramming/VBG
during/IN
EBV-mediated/JJ
Bcell/NN
transformation/NN
(/(
Janz/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Therefore/RB
,/,
GAPDH/NN
may/MD
not/RB
be/VB
suitable/JJ
for/IN
internal/JJ
controls/NNS
in/IN
gene/NN
expression/NN
analyses/NNS
between/IN
B-cells/NNS
and/CC
LCLs/NNS
./.
====================
Furthermore/RB
,/,
a/DT
correlation/NN
coefficient/JJ
analysis/NN
for/IN
gene/NN
expression/NN
profiles/NNS
,/,
normalized/VBN
by/IN
four/CD
housekeeping/JJ
genes/NNS
,/,
showed/VBD
that/IN
TBP/NN
was/VBD
found/VBN
to/TO
be/VB
a/DT
suitable/JJ
internal/JJ
control/JJ
in/IN
the/DT
gene/NN
expression/NN
analysis/NN
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
./.
====================
Moreover/RB
,/,
TBP/NN
expression/NN
level/NN
was/VBD
found/VBN
to/TO
be/VB
moderately/RB
abundant/JJ
in/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
,/,
as/IN
determined/VBN
by/IN
the/DT
CT/NN
difference/NN
between/IN
genes/NNS
of/IN
interest/NN
and/CC
TBP/NN
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Although/IN
many/JJ
other/JJ
housekeeping/JJ
genes/NNS
were/VBD
not/RB
evaluated/VBN
in/IN
this/DT
study/NN
,/,
at/IN
least/JJS
TBP/NN
can/MD
be/VB
used/VBN
as/IN
an/DT
optimum/JJ
internal/JJ
control/JJ
for/IN
gene/NN
expression/NN
analysis/NN
,/,
regardless/RB
of/IN
the/DT
status/NN
of/IN
Bcells/NNS
(/(
e./FW
g./FW
,/,
primary/JJ
,/,
EBV-infected/JJ
B-cells/NNS
)/)
or/CC
longterm/JJ
subculture/NN
of/IN
LCLs/NNS
./.
====================
Thus/RB
,/,
we/PRP
finally/RB
selected/VBN
TBP/NN
as/IN
a/DT
normalizer/JJ
for/IN
further/JJ
gene/NN
expression/NN
studies/NNS
of/IN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
./.
====================
It/PRP
is/VBZ
known/VBN
that/IN
the/DT
hematopoietic/JJ
genes/NNS
that/WDT
were/VBD
selected/VBN
for/IN
this/DT
study/NN
are/VBP
involved/VBN
in/IN
hematopoiesis/NN
and/CC
lymphoid/JJ
malignancies/NNS
./.
====================
For/IN
example/NN
,/,
PLAGL2/NN
,/,
a/DT
developmentally/RB
regulated/VBN
C2H2/NN
zinc/NN
finger/NN
on/IN
chromosome/NN
8q12/NN
,/,
is/VBZ
the/DT
main/JJ
target/NN
for/IN
pleomorphic/JJ
adenomas/NNS
of/IN
the/DT
salivary/JJ
gland/NN
./.
====================
Recently/RB
,/,
it/PRP
was/VBD
reported/VBN
that/IN
PLAGL2/NN
induced/VBD
acute/JJ
myeloid/JJ
leukemia/NN
in/IN
cooperation/NN
with/IN
CBFB-MYH11/NN
in/IN
mice/NNS
(/(
Landrette/JJ
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Our/PRP$
results/NNS
showed/VBD
that/IN
PLAGL2/NN
was/VBD
upregulated/VBN
in/IN
EBV-infected/JJ
B-cells/NNS
and/CC
LCLs/NNS
,/,
suggesting/VBG
that/IN
PLAGL2/NN
may/MD
be/VB
a/DT
potential/JJ
target/NN
of/IN
EBV-mediated/JJ
Bcell/NN
transformation/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
RUNX/NN
family/NN
members/NNS
are/VBP
heterodimeric/JJ
transcription/NN
factors/NNS
composed/VBN
of/IN
an/DT
α/JJ
subunit/NN
,/,
RUNX/NN
,/,
and/CC
a/DT
β/JJ
subunit/NN
,/,
CBFβ/NN
./.
====================
Of/IN
the/DT
three/CD
members/NNS
of/IN
the/DT
RUNX/NN
family/NN
,/,
RUNX1/NN
is/VBZ
known/VBN
as/IN
a/DT
master/JJ
regulatory/JJ
gene/NN
of/IN
hematopoiesis/NN
./.
====================
According/VBG
to/TO
the/DT
literature/NN
,/,
RUNX3/NN
was/VBD
identified/VBN
as/IN
a/DT
cellular/JJ
target/NN
of/IN
EBNA2/NN
in/IN
the/DT
inducible/JJ
cell/NN
line/NN
(/(
Spender/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
The/DT
distal/JJ
P1/NN
promoter/NN
of/IN
RUNX1/NN
controls/NNS
expression/NN
of/IN
the/DT
RUNX1c/NN
isoform/NN
,/,
while/IN
the/DT
proximal/JJ
P2/NN
promoter/NN
expresses/VBZ
RUNX1a/NN
(/(
AML1a/NN
)/)
and/CC
RUNX1b/NN
(/(
AML1b/NN
)/)
(/(
Miyoshi/NNP
et/FW
al./FW
,/,
1991/CD
)/)
./.
====================
RUNX3/NN
represses/VBZ
transcription/NN
from/IN
the/DT
RUNX1/NN
P1/NN
promoter/NN
,/,
indicating/VBG
transcriptional/JJ
crossregulation/NN
of/IN
RUNX1/NN
by/IN
RUNX3/NN
in/IN
human/JJ
B/NN
cells/NNS
(/(
Spender/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
On/IN
the/DT
contrary/JJ
,/,
our/PRP$
PCR/NN
results/NNS
showed/VBD
that/IN
RUNX1/NN
expression/NN
was/VBD
downregulated/VBN
in/IN
parallel/JJ
with/IN
slight/JJ
downregulation/NN
of/IN
RUNX3/NN
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
,/,
which/WDT
is/VBZ
inconsistent/JJ
with/IN
a/DT
previous/JJ
report/NN
of/IN
crossregulation/NN
by/IN
RUNX3/NN
./.
====================
This/DT
discrepancy/NN
might/MD
be/VB
due/JJ
to/TO
a/DT
different/JJ
PCR/NN
target/NN
of/IN
RUNX1/NN
isoforms/NNS
,/,
because/IN
the/DT
RUNX/NN
isoform/NN
that/IN
we/PRP
examined/VBD
in/IN
our/PRP$
study/NN
was/VBD
the/DT
RUNX1/NN
P2/NN
transcript/NN
rather/RB
than/IN
RUNX1/NN
P1/NN
transcripts/NNS
./.
====================
Musculin/NN
(/(
activated/VBN
Bcell/NN
factor1/NN
,/,
MSC/NN
)/)
is/VBZ
a/DT
basic/JJ
helixloophelix/JJ
transcription/NN
factor/NN
,/,
and/CC
its/PRP$
expression/NN
is/VBZ
restricted/JJ
to/TO
a/DT
subset/NN
of/IN
lymphoid/JJ
tissues/NNS
,/,
lymphoblastoid/JJ
cell/NN
lines/NNS
,/,
and/CC
activated/VBD
human/JJ
B/NN
cells/NNS
./.
====================
MSC/NN
(/(
ABF1/NN
)/)
expression/NN
is/VBZ
restricted/JJ
to/TO
a/DT
subset/NN
of/IN
lymphoid/JJ
tissues/NNS
,/,
lymphoblastoid/JJ
cell/NN
lines/NNS
,/,
and/CC
activated/VBD
human/JJ
B/NN
cells/NNS
(/(
Massari/NNP
et/FW
al./FW
,/,
1998/CD
)/)
,/,
suggesting/VBG
that/IN
MSC/NN
is/VBZ
a/DT
downstream/JJ
target/NN
of/IN
the/DT
Bcell/NN
receptor/NN
signal/NN
transduction/NN
pathway/NN
./.
====================
With/IN
respect/NN
to/TO
cell/NN
growth/NN
,/,
EBV/NN
infection/NN
mimics/VBZ
Bcell/NN
activation/NN
signals/NNS
or/CC
factors/NNS
,/,
such/JJ
as/IN
CD40CD40L/JJ
,/,
IgM/NN
,/,
and/CC
LPS/NN
,/,
so/RB
that/IN
EBVinfected/JJ
Bcells/NNS
exhibit/VBP
greater/JJR
proliferation/NN
than/IN
resting/VBG
Bcells/NNS
(/(
Kilger/NN
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Thus/RB
,/,
the/DT
upregulation/NN
of/IN
MSC/NN
in/IN
LCLs/NNS
might/MD
be/VB
responsible/JJ
for/IN
greater/JJR
proliferative/JJ
activity/NN
in/IN
EBVinfected/JJ
Bcells/NNS
compared/VBN
with/IN
Bcells/NNS
./.
====================
TLE/NN
(/(
transducinlike/JJ
enhancer/NN
of/IN
split/NN
)/)
genes/NNS
are/VBP
human/JJ
homologs/NNS
of/IN
the/DT
Drosophila/NN
groucho/NN
gene/NN
./.
====================
TLE1/NN
binds/VBZ
to/TO
the/DT
Runt/NN
domain/NN
and/CC
the/DT
C/NN
terminus/NN
of/IN
RUNX1/NN
to/TO
inhibit/VB
RUNX1induced/JJ
transactivation/NN
of/IN
the/DT
CSF1/NN
(/(
colony/NN
stimulating/NN
factor/NN
1/CD
)/)
receptor/NN
./.
====================
Our/PRP$
PCR/NN
analysis/NN
showed/VBD
that/IN
TLE1/NN
and/CC
NOTCH2/NN
were/VBD
downregulated/VBN
in/IN
LCLs/NNS
compared/VBN
with/IN
Bcells/NNS
,/,
suggesting/VBG
that/IN
Notch/NN
signaling/NN
may/MD
be/VB
involved/VBN
in/IN
EBVmediated/JJ
Bcell/NN
transformation/NN
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
that/WDT
were/VBD
tested/VBN
in/IN
this/DT
study/NN
may/MD
be/VB
potential/JJ
cellular/JJ
targets/NNS
of/IN
EBV/NN
infection/NN
during/IN
LCL/NN
generation/NN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
evaluated/VBD
four/CD
common/JJ
internal/JJ
controls/NNS
for/IN
a/DT
gene/NN
expression/NN
analysis/NN
between/IN
B/NN
cells/NNS
and/CC
LCLs/NNS
and/CC
found/VBD
TBP/NN
as/IN
a/DT
suitable/JJ
internal/JJ
control/JJ
./.
====================
Expression/NN
analysis/NN
using/VBG
a/DT
TBP/NN
normalizer/CC
allowed/VBD
us/PRP
to/TO
identify/VB
dramatic/JJ
changes/NNS
in/IN
selected/VBN
hematopoietic/JJ
transcriptional/JJ
regulatory/JJ
genes/NNS
(/(
downregulation/NN
of/IN
RUNX1/NN
,/,
RUNX3/NN
,/,
CBFB/NN
,/,
TLE1/NN
,/,
and/CC
NOTCH2/NN
;/:
upregula/IN
tion/NN
of/IN
MSC/NN
and/CC
PLAGL2/NN
)/)
during/IN
EBV-mediated/JJ
Bcell/NN
transformation/NN
and/CC
LCLs/NNS
at/IN
different/JJ
passages/NNS
./.
====================
Therefore/RB
,/,
these/DT
genes/NNS
may/MD
be/VB
potential/JJ
cellular/JJ
targets/NNS
of/IN
EBV/NN
infection/NN
and/CC
potential/JJ
reference/VBP
biomarkers/NNS
of/IN
LCL/NN
generation/NN
./.
====================
This/DT
work/NN
was/VBD
supported/VBN
by/IN
an/DT
intramural/JJ
grant/JJ
(/(
2010/CD
N74001-00/CD
)/)
of/IN
Korea/NN
National/JJ
Institute/JJ
of/IN
Health/NN
,/,
Korea/NN
Centers/NNS
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
./.
====================
